The research process for new drug is complicated, time-consuming, and costly. Thousands of chemical compounds must be made and tested in an effort to find one that can achieve a desirable result. It may take approximately ten years to study and test a new drug before it can be approved for the general public. However, in today's pharmaceutical industry drug delivery has become keys in drug prod...

Pharmaceutical wastewaters are generated through complex manufacturing processes that contain a variety of organic and inorganic constituents, and are usually characterized by a high concentration of chemical oxygen demand (COD), suspended solids, dissolved solids (salts), toxicity, and refractory compounds. Therefore, it must be treated. The treatment of a pharmaceutical wastewater (PWW) using...

The pharmaceutical industry is knowledge and research-intensive. Due to technological, socio-political and organisational changes there has been a continuous evolution in the knowledge base utilized to achieve and maintain competitive advantages in this global industry. There is a gap in analysing the linkages and effects of those changes on knowledge creation processes associated with pharmace...

Recently, the major area of concern is the presence of the emerging pollutants in wastewaters, surface waters and ground waters. In most cases, the emerging contaminants refers to the unregulated pollutants, which can be included for future regulation depending upon research on their health effects and their occurrence. They generally includes surfactants, illicit drugs, endocrine disruptors, p...

The Act on the Reform of the Market for Medicinal Products (“AMNOG”) introduced an early benefit assessment (EBA) of pharmaceuticals in Germany in 2011. According to this law, all pharmaceuticals with a new active agent made available on the market for the first time have to go through a benefit assessment process. A benefit assessment dossier has to be submitted at the time of the market entry...

Three recent systematic reviews have shown that pharmaceutical industry funding of clinical trials is strongly associated with pro-industry results. This article builds on those analyses, situating funding's effects in the context of the ghost-management of research and publication by pharmaceutical companies, and the creation of social ties between those companies and researchers. There are mu...

While pharmaceutical patent terms have increased in Canada, increases in patented drug spending have been mitigated by price controls and retrenchment of public prescription drug subsidy programs. We estimate the net effects of these offsetting policies on domestic pharmaceutical R&D expenditures and also provide an upper-bound estimate on the effects of these policies on Canadian pharmaceutica...

Retail sales of prescription drugs totaled $154.5 billion in 2001. The National Institute for Health Care Management estimates annual sales will exceed $400 billion by the year 2010. This paper analyzes the welfare and distributional effects of two policy families that could be used to cope with high and rising pharmaceutical costs. We employ a general-equilibrium approach to contrast the curre...

The price effects of the Swedish pharmaceutical substitution reform are analyzed using data for a panel of all pharmaceutical product sold in Sweden in 1997-2007. The price reduction due to the reform was estimated to average 10% and was found to be significantly larger for brand-name pharmaceuticals than for generics. The results also imply that the reform amplified the effect that generic ent...